Drug Trial Radar · NCT05994131
IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
110
Planned (sponsor's estimate)
Start
Jul 13, 2023
Primary completion
Sep 20, 2025
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- InxMed (Shanghai) Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 16, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, open-label, phase Ib/II clinical study to evaluate the safety, tolerability, pharmacokinetics and antitumor efficacy of IN10018 in combination with third-generation EGFR-TKI (Furmonertinib is the proposed) in previously-treated or naïve advanced EGFR-mutation positive NSCLC.
Conditions
- NSCLC
Interventions
IN10018Drug
orally taken once daily
FurmonertinibDrug
orally taken once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Recommended phase II dose (RP2D) of IN10018 in combination with third-generation EGFR-TKI in subjects with advanced EGFR mutation-positive NSCLC.Time frame: 3 years
- ORR of IN10018 in combination with third-generation EGFR-TKI in subjects with advanced EGFR mutation-positive NSCLC.Time frame: 3 years
- Tumor Shrinkage Rate (TSR) of IN10018 in combination with third-generation EGFR-TKI in cohort 3 of advanced treatment-naive EGFR mutation-positive NSCLC.Time frame: 3 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Pulmonary Hospital
Shanghai, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.